Actively Recruiting
Early and Objective Assessment of Neurological Prognosis in Cardiac Arrest Patients
Led by Nantes University Hospital · Updated on 2025-02-26
608
Participants Needed
4
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a study to improve the early prediction of brain damage in patients who have been resuscitated after cardiac arrest and admitted to intensive care. Brain injuries cause many deaths in these patients, so identifying who has neurological lesions is important for targeting neuroprotective treatments. The study aims to develop a simple and quick tool to assess brain injury severity early on, helping guide care decisions without exposing patients without lesions to unnecessary treatments. This research is an observational trial where investigators will measure specific biomarkers, UCHL-1 and GFAP, when patients arrive in intensive care. These biomarkers are proteins linked to brain injury. The study will also track neurological outcomes 90 days after enrollment using the modified Rankin scale. The goal is to see how well early biomarker levels predict later brain function. Participants will be adults admitted to intensive care after out-of-hospital cardiac arrest who are comatose on arrival. Researchers will collect biomarker samples at admission and again 4 hours after recovery of effective cardiac activity. They will monitor neurological status over 90 days to evaluate outcomes. The study seeks to provide reliable early information to improve post-cardiac arrest care while avoiding unnecessary treatments for those without brain injury.
CONDITIONS
Brief Title
Early and Objective Assessment of Neurological Prognosis in Cardiac Arrest Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Admitted to intensive care after out-of-hospital cardiac arrest
- Comatose on admission with Glasgow coma score of 8 or less
- Informed consent provided by a relative or inclusion under emergency procedure if no relative is available
You will not qualify if you...
- Cardiac arrest that occurred in hospital
- Age younger than 18 years
- Under guardianship or legal protection
- Previously included in this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within the first day of ICU admission
Participants undergo biomarker dosage assessments at intensive care unit admission and at 4 hours for recovery of effective cardiac activity.
2 visits (in-person) at ICU admission and 4 hours later
Duration - 90 days
Participants' neurological outcomes are assessed 90 days after enrolment using the modified Rankin scale (mRS).
1 follow-up visit (in-person or remote)
Trial Site Locations
Total: 4 locations
1
CHD Vendée
La Roche-sur-Yon, France, 85025
Actively Recruiting
2
CHU Nantes
Nantes, France, 44093
Actively Recruiting
3
APHP - Hôpital Cochin
Paris, France, 75679
Actively Recruiting
4
CH Saint-Nazaire
Saint-Nazaire, France, 44600
Actively Recruiting
Research Team
J
Jean-Baptiste LASCARROU
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here